One of the best examples is breast cancer, where patients with abnormally high levels of HER2 protein in their tumour (HER2+ breast cancer) greatly benefit from combining trastuzumab (Herceptin®, anti-HER2) with chemotherapy [294]. Here, ERBB2 is linked to neoplasm.